A Randomized, Open Label, Multicenter Phase 2 Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RESORT
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2017 Planned End Date changed from 1 Sep 2016 to 1 Sep 2019.
- 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology